Advanced Biomedical Research

Efficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasis

Authors

Department of Dermatology, Skin Diseases and Leishmaniasis Research Centre, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Psoriasis is a common dermatologic disorder, with fluctuating response to treatment. Considering the proven immunomodulatory effects of oral simvastatin in psoriasis, this trial study was enrolled to determine whether the topical form has also antipsoriatic effects. Vitamin D analogs known to be effective and are considered the first line of therapy in mild to moderate cases. In this study, the efficacy of topical calcipotriol 0.005% ointment (as a standard method of treatment for psoriasis) versus combination of calcipotriol plus topical simvastatin is compared in the treatment of psoriasis.
Materials and Methods: A total of 80 subjects with symmetric psoriasis who had body surface involvement up to 20% were divided randomly into 2 groups. Group A were treated with calcipotriol 0.005% ointment twice daily and Group B with calcipotriol 0.005% ointment twice daily and simvastatin 3% ointment twice daily for 12 weeks. The results were evaluated by a Blind Dermatologist using psoriasis area severity index (PASI) score at baseline, 4 th , 8 th and 12 th week of treatment. In a similar way, a subjective assessment performed by patients based on photo-evaluation at the end of the study.
Results: Despite a continuous reduction in PASI score in both groups, according to both physician (P = 0.603) and patient (P = 0.243) assessment topical simvastatin was not statistically more effective than conventional treatment of psoriasis at the end of the study.
Conclusion: This study indicates that topical simvastatin is not associated with significant impacts in the treatment of psoriasis as compared to oral form. This study indicates that psoriasis is a systemic disorder with variable skin manifestations.

Keywords

1. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.  Back to cited text no. 1
[PUBMED]    
2. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 national psoriasis foundation patient-membership survey. Arch Dermatol 2001;137:280-4.  Back to cited text no. 2
[PUBMED]    
3. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003;49 Suppl 2:57-61.  Back to cited text no. 3
    
4. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: A systematic literature review. J Investig Dermatol Symp Proc 2004;9:140-7.  Back to cited text no. 4
[PUBMED]    
5. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006;54:685-704.  Back to cited text no. 5
[PUBMED]    
6. van de Kerkhof P, Nestle F. Psoriasis. In: Bolognia J, Jorizzo J, Schaffer J, editors. Dermatolog. 3 rd edition: Elsevier Saunders; 2012. p.135-56.  Back to cited text no. 6
    
7. Barnes L, Altmeyer P, Fôrstrôm L, Stenström MH. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 2000;10:199-204.  Back to cited text no. 7
    
8. Gottlieb AB. Psoriasis: Emerging therapeutic strategies. Nat Rev Drug Discov 2005;4:19-34.  Back to cited text no. 8
[PUBMED]    
9. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, et al. Biological therapies in the systemic management of psoriasis: International consensus conference. Br J Dermatol 2004;151 Suppl 69:3-17.  Back to cited text no. 9
[PUBMED]    
10. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.  Back to cited text no. 10
[PUBMED]    
11. Dobreanu M, Dobreanu D, Fodor A, Bacarea A. Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin. Rom J Intern Med 2007;45:193-9.  Back to cited text no. 11
[PUBMED]    
12. Yamashita M, Otsuka F, Mukai T, Otani H, Inagaki K, Miyoshi T, et al. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol 2008;196:601-13.  Back to cited text no. 12
[PUBMED]    
13. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: A new therapeutic target in inflammatory dermatoses. J Dermatolog Treat 2008;19:318-26.  Back to cited text no. 13
[PUBMED]    
14. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007;13:711-8.  Back to cited text no. 14
[PUBMED]    
15. Namazi MR. Statins: Novel additions to the dermatologic arsenal? Exp Dermatol 2004;13:337-9.  Back to cited text no. 15
[PUBMED]    
16. Späh F. Inflammation in atherosclerosis and psoriasis: Common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008;159 Suppl 2:10-7.  Back to cited text no. 16
    
17. Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol 2007;57:529-31.  Back to cited text no. 17
[PUBMED]    
18. Naseri M, Hadipour A, Sepaskhah M, Namazi MR. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: A double-blind, randomized, placebo-controlled study. Niger J Med 2010;19:58-61.  Back to cited text no. 18
[PUBMED]    
19. Otuki MF, Pietrovski EF, Cabrini DA. Topical simvastatin: Preclinical evidence for a treatment of skin inflammatory conditions. J Dermatol Sci 2006;44:45-7.  Back to cited text no. 19
    
20. Adami M, Prudente Ada S, Mendes DA, Horinouchi CD, Cabrini DA, Otuki MF. Simvastatin ointment, a new treatment for skin inflammatory conditions. J Dermatol Sci 2012;66:127-35.  Back to cited text no. 20
[PUBMED]    
21. Fredriksson T, Pettersson U. Severe psoriasis - Oral therapy with a new retinoid. Dermatologica 1978;157:238-44.  Back to cited text no. 21
[PUBMED]    
22. Flytström I, Stenberg B, Svensson Å, Bergbrant IM. Patients' visual analogue scale: A useful method for assessing psoriasis severity. Acta Derm Venereol 2012; 92:347-8.  Back to cited text no. 22
    
23. Kragballe K. Vitamin D in Dermatology. New York: Marcel Dekker; 2000.  Back to cited text no. 23
    
24. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009;119:3573-85.  Back to cited text no. 24
[PUBMED]    
25. Krueger JG, Bowcock A. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis 2005;64 Suppl 2:ii30-6.  Back to cited text no. 25
[PUBMED]    
26. Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001;131:41-6.  Back to cited text no. 26
[PUBMED]    
27. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003;170:1524-30.  Back to cited text no. 27
[PUBMED]    
28. Fenton C, Plosker GL. Calcipotriol/betamethasone dipropionate: A review of its use in the treatment of psoriasis vulgaris. Am J Clin Dermatol 2004;5:463-78.  Back to cited text no. 28
[PUBMED]    
29. Feldman SR, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, et al. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: Results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Am J Clin Dermatol 2012;13:261-71.  Back to cited text no. 29
[PUBMED]    
30. Wolkenstein P, Revuz J, Roujeau JC, Bonnelye G, Grob JJ, Bastuji-Garin S, et al. Psoriasis in France and associated risk factors: Results of a case-control study based on a large community survey. Dermatology 2009;218:103-9.  Back to cited text no. 30
    
31. Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 2009;22:61-73.  Back to cited text no. 31
[PUBMED]    
32. Gambhire M, Bhalekar M, Shrivastava B. Bioavailability assessment of simvastatin loaded solid lipid nanoparticles after oral administration. J Pharm Sci 2011;6:251-8.  Back to cited text no. 32
Advanced Biomedical Research
Volume 2014, January
January 2014
Pages 1-6